TRAW icon

Traws Pharma

2.81 USD
+0.16
6.04%
At close Mar 18, 4:00 PM EDT
After hours
2.66
-0.15
5.34%
1 day
6.04%
5 days
-3.10%
1 month
-44.47%
3 months
-46.07%
6 months
-63.51%
Year to date
-67.59%
1 year
-87.08%
5 years
-97.42%
10 years
-100.00%
 

About: Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Employees: 17

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

170% more capital invested

Capital invested by funds: $3.8M [Q3] → $10.2M (+$6.45M) [Q4]

73% more funds holding

Funds holding: 11 [Q3] → 19 (+8) [Q4]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

3.31% more ownership

Funds ownership: 35.32% [Q3] → 38.63% (+3.31%) [Q4]

53% less call options, than puts

Call options by funds: $178K | Put options by funds: $376K

Research analyst outlook

We haven’t received any recent analyst ratings for TRAW.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline results from ferrets infected with H5N1 bird flu, an accepted animal model for human influenza, when treated with tivoxavir marboxil as a single dose. These data are consistent with results reported in December 2024 in a murine model. The new studies reported today evaluated the efficacy of a single dose of tivoxavir marboxil as a treatment for bird flu isolated from a Texas dairy worker and showed suppression of disease, with reduced viral burden in lungs.
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Neutral
GlobeNewsWire
2 weeks ago
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders' equity requirements of Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”.
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
Neutral
PRNewsWire
1 month ago
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa. , Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir), for the treatment or prevention of H5N1 bird flu.
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Neutral
PRNewsWire
2 months ago
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially pivotal advance in addressing this serious health challenge.
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
Neutral
PRNewsWire
2 months ago
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting readouts NEWTOWN, Pa. , Dec. 30, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases including bird flu, today announced that it has entered into definitive agreements to raise up to $72.6 million before deduction of placement agent's fees and other estimated offering expenses.
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Positive
Invezz
2 months ago
Traws Pharma stock soars 200% on encouraging bird flu drug data
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I clinical trial.
Traws Pharma stock soars 200% on encouraging bird flu drug data
Neutral
PRNewsWire
2 months ago
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers   Potent inhibition of drug-resistant and bird flu viruses in vitro In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phase 2 study expected to begin in H1 2025 Traws Pharma is expanding its influenza program to address the potential threat of bird flu NEWTOWN, Pa. , Dec. 23, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu.
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Neutral
GlobeNewsWire
4 months ago
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024.
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
Neutral
GlobeNewsWire
5 months ago
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of Phase 2 dose Preclinical data showed potent inhibition of drug-resistant and bird influenza viruses Phase 2 study expected to begin in H1 2025 Improved therapy is an important need for both seasonal and pandemic flu NEWTOWN, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir).
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Neutral
GlobeNewsWire
5 months ago
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Charts implemented using Lightweight Charts™